Navigation Links
Gen-Probe Reports Financial Results for Second Quarter 2009
Date:7/30/2009
SAN DIEGO, July 30 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: GPRO) today reported financial results for the second quarter of 2009, including non-GAAP earnings per share (EPS) of $0.45 and record sexually transmitted disease (STD), clinical diagnostics and total product sales.
"Gen-Probe posted solid earnings in the second quarter of 2009 as a good performance from our core STD franchise, the inclusion of initial revenues from our Tepnel acquisition, and portfolio gains outweighed lower-than-expected blood screening sales," said Carl Hull, the Company's president and chief executive officer. "In addition, the key R&D projects that we expect to boost future growth - including our PANTHER instrument and new tests for human papillomavirus (HPV), prostate cancer and trichomonas - remain on track."
In the second quarter of 2009, product sales were $116.8 million, compared to $113.7 million in the prior year period, an increase of 3%. Compared to the second quarter of 2008, the stronger U.S. dollar reduced product sales growth by an estimated 4%(2). Total revenues for the second quarter of 2009 were $120.5 million, compared to $119.8 million in the prior year period, an increase of 1%.
Net income was $23.2 million ($0.45 per share) on a non-GAAP basis in the second quarter of 2009, compared to $24.8 million ($0.45 per share) in the prior year period, a decrease of 6%. Including $4.4 million ($0.07 per share) of expenses related to the Company's acquisition of Tepnel, which closed on April 8, 2009, net income in the second quarter of 2009 was $19.8 million ($0.38 per share) on a GAAP basis.
For the first six months of 2009, product sales were $229.3 million, compared to $215.2 million in the prior year period, an increase of 7%.
'/>"/>
| SOURCE Gen-Probe Incorporated Copyright©2009 PR Newswire. All rights reserved |
Related medicine news :
1. Gen-Probe to Webcast Two Upcoming Investor Presentations
2. Gen-Probe Reports Financial Results for First Quarter 2009
3. Gen-Probe, Roche Prevail in Arbitration With Digene Concerning Human Papillomavirus Agreement
4. Gen-Probe Board of Directors Elects Carl Hull Chief Executive Officer
5. Tepnel Shareholders Approve Acquisition by Gen-Probe
6. Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2008
7. Gen-Probe to Acquire Tepnel Life Sciences, Fast-Growing European Molecular Diagnostics Company, for 92.8 Million Pounds Sterling ($132.2 Million) in Cash
8. Gen-Probe and Novartis Agree to Extend and Expand Blood Screening Collaboration
9. Eric Tardif Joins Gen-Probe as Senior Vice President, Corporate Strategy
10. Gen-Probe to Webcast Presentation at the 27th Annual J.P. Morgan Healthcare Conference
11. Gen-Probe to Webcast Presentation at the 20th Annual Piper Jaffray Health Care Conference
Post Your Comments:
(Date:6/19/2013)... 2013 Kleritec, Inc. announced the addition ... http://www.kleritec.com . In the recent expansion Kleritec ... activities packages for pre-school and day care providers. The ... to aid teachers across the United States the ability ... , Included in the art and activities packages is ...
(Date:6/19/2013)... York, NY (PRWEB) June 19, 2013 Citi Bike ... There’s no way for Dr. David Perna to know for sure ... service, but he’s happy that they’ll have the option. In ... healthier lives—especially if it might also make it more convenient for ... Dr. Perna is the Director of Complimentary Alternative Medicine at Back ...
(Date:6/19/2013)... a major international study led by researchers at The ... therapy ibrutinib continues to show remarkable promise for the ... , The most recent interim findings of the 18-center ... New England Journal of Medicine . Previous interim findings ... Society of Hematology Annual Meeting and Exposition. , ...
(Date:6/19/2013)... as many emergency department visits if their primary care ... days a week, according to new research from child ... Hopkins University. , The new study was published online ... and will be presented at the AcademyHealth Annual Research ... understanding where primary care practices and medical home programs ...
(Date:6/19/2013)... Nearly 70 percent of Americans are on ... half take two, Mayo Clinic researchers say. Antibiotics, ... their study found. Twenty percent of patients are ... the findings, published online in the journal ... audio and video of Dr. Jennifer St. Sauver ...
Breaking Medicine News(10 mins):Health News:Kleritec Announces Addition of Educational Products. 2Health News:New York City's Back and Body Medical Welcomes Citi Bike to Midtown Manhattan 2Health News:New York City's Back and Body Medical Welcomes Citi Bike to Midtown Manhattan 3Health News:Ibrutinib continues strong showing against mantle cell lymphoma 2Health News:Extended primary care office hours might help keep kids out of the emergency department 2Health News:Nearly 7 in 10 Americans are on prescription drugs, Mayo Clinic study finds 2[0] Kleritec Announces Addition of Educational Products.[0] New York City's Back and Body Medical Welcomes Citi Bike to Midtown Manhattan[0] Ibrutinib continues strong showing against mantle cell lymphoma[0] Extended primary care office hours might help keep kids out of the emergency department[0] Nearly 7 in 10 Americans are on prescription drugs, Mayo Clinic study finds
... , , MIAMI, Dec. ... creator of the immensely popular Dr. Siegal,s COOKIE DIET® weight-loss ... brand,s global distributor, this morning filed a lawsuit against reality ... made on her Twitter page on October 29, 2009. A ...
... SAN JOSE, Calif. , Dec. 29 The Coalition for ... advocacy, research support and awareness, even in a year plagued ... has no known cause, no FDA-approved treatment, and no cure. ... advancing the effort to build awareness of the disease throughout ...
... , Advisories Eased for Seven Water Bodies; ... State officials today released updated fish consumption advisories that ... had not previously been on the list, but also eases ... , The advisories were developed through an interagency partnership between ...
... , ... heels of its remarkable success in alcohol recovery, National Institute For Alcohol Recovery (NIFAR®) ... resolutions....(read more) , ... Gaithersburg, MD (PRWEB) December 29, 2009 -- On the heels of its remarkable success ...
... type 2 diabetes, prediabetes sooner, with no fasting, , TUESDAY, ... clinical guidelines, the American Diabetes Association is promoting a more ... diagnosis of type 2 diabetes and prediabetes. , Long used ... average blood sugar levels for the previous two to three ...
... , WASHINGTON, Dec. 29 ... Wellness Challenge -- three promotions spanning the next five ... their health goals in 2010. , "The goal of ... change their wellness habits, which can be difficult," says William ...
Cached Medicine News:Health News:Kim Kardashian Sued by Dr. Siegal's COOKIE DIET(R) Creator Dr. Sanford Siegal 2Health News:Kim Kardashian Sued by Dr. Siegal's COOKIE DIET(R) Creator Dr. Sanford Siegal 3Health News:Kim Kardashian Sued by Dr. Siegal's COOKIE DIET(R) Creator Dr. Sanford Siegal 4Health News:Kim Kardashian Sued by Dr. Siegal's COOKIE DIET(R) Creator Dr. Sanford Siegal 5Health News:Coalition for Pulmonary Fibrosis Celebrates Successes Despite Year of Economic Downturn 2Health News:Coalition for Pulmonary Fibrosis Celebrates Successes Despite Year of Economic Downturn 3Health News:Coalition for Pulmonary Fibrosis Celebrates Successes Despite Year of Economic Downturn 4Health News:Updated Fish Consumption Advisories Issued for 2010 2Health News:Updated Fish Consumption Advisories Issued for 2010 3Health News:Now Millions Suffering With Alcohol Addiction Can Get Breakthrough Recovery in Ultimate Privacy 2Health News:Now Millions Suffering With Alcohol Addiction Can Get Breakthrough Recovery in Ultimate Privacy 3Health News:New Guidelines Urge A1C Test for Diabetes Diagnosis 2Health News:'Life...supplemented' Announces America's Wellness Challenge 2Health News:'Life...supplemented' Announces America's Wellness Challenge 3Kim Kardashian Sued by Dr. Siegal's COOKIE DIET(R) Creator Dr. Sanford SiegalCoalition for Pulmonary Fibrosis Celebrates Successes Despite Year of Economic DownturnUpdated Fish Consumption Advisories Issued for 2010Now Millions Suffering With Alcohol Addiction Can Get Breakthrough Recovery in Ultimate PrivacyNew Guidelines Urge A1C Test for Diabetes Diagnosis'Life...supplemented' Announces America's Wellness Challenge
(Date:6/19/2013)... The Physician-Patient Alliance for Health & Safety recently released three ... urgently address this issue has been emphasized by The ... device alarm safety in hospitals." According to The Joint Commission ... there were 98 alarm related events reported, of which: ... resulted in permanent loss of function (13%) , 5 ...
(Date:6/19/2013)... NEW YORK , June 19, 2013 ... dedicated to finding a cure for brain cancer, today ... ) a grant to support the clinical investigation of ... a recurrent high grade glioma brain cancer (Grade 3 ... company developing novel treatments for advanced cancer, with an ...
(Date:6/19/2013)... Nektar Therapeutics (Nasdaq: NKTR ) ... (HAL) study for NKTR-181, a first-in-class, opioid analgesic ... This slow rate of entry is designed to reduce the ... to current opioid analgesics. 1 In the study data ... placebo in "drug liking" and "feeling high" scores and had ...
Breaking Medicine Technology:Three Lessons Learned to Reduce Alarm Fatigue and Improve Alarm Management and Patient Safety in Hospitals 2Three Lessons Learned to Reduce Alarm Fatigue and Improve Alarm Management and Patient Safety in Hospitals 3Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 2Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 2Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 4Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 5Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 6Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 7Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 8Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 9[0] Three Lessons Learned to Reduce Alarm Fatigue and Improve Alarm Management and Patient Safety in Hospitals[0] Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer[0] Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
... Study Showed 11 Percent Fewer RA Patients,Reported ... Therapy,Compared to Methotrexate Alone, BARCELONA, Spain, June ... one of the most common causes of,disability ... today show that,rheumatoid arthritis (RA) patients treated ...
... Influenza Conference, HIGH WYCOMBE, England, June 18, 2007 ... new flu vaccine has the,potential to protect against ... presented today by PepTcell, at the 2007,Options for ... Canada. , The pre-clinical results, which will be ...
Cached Medicine Technology:Three Studies Suggest Abbott's Humira (adalimumab) May Improve Work,Productivity in Patients with Rheumatoid Arthritis 2Three Studies Suggest Abbott's Humira (adalimumab) May Improve Work,Productivity in Patients with Rheumatoid Arthritis 3Three Studies Suggest Abbott's Humira (adalimumab) May Improve Work,Productivity in Patients with Rheumatoid Arthritis 4Three Studies Suggest Abbott's Humira (adalimumab) May Improve Work,Productivity in Patients with Rheumatoid Arthritis 5Three Studies Suggest Abbott's Humira (adalimumab) May Improve Work,Productivity in Patients with Rheumatoid Arthritis 6Three Studies Suggest Abbott's Humira (adalimumab) May Improve Work,Productivity in Patients with Rheumatoid Arthritis 7New Flu Vaccine From PepTcell Could Provide Immunity Against All,Strains of Influenza Virus 2New Flu Vaccine From PepTcell Could Provide Immunity Against All,Strains of Influenza Virus 3New Flu Vaccine From PepTcell Could Provide Immunity Against All,Strains of Influenza Virus 4For rigid cystoscopes and rigid-, and semi-rigid ureteroscopes, these forceps have an integral handle design and a diameter of 5 Fr with a working length of 58 cm....
Fulgurating Electrode, 2 F...
Used to obtain biopsy specimens from pathological lesions in the ureter, renal pelvis, infundibula, or calyces. Supplied sterile in peel-open packages. Intended for one-time use....
Used to obtain tissue biopsy under direct vision. Cup Biopsy Forceps are designed for use through rigid or flexible endoscopes. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products:| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |